scholarly journals THE IMPACT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON ASYMMETRIC DIMETHYLARGININE IN ORTHOTOPIC HEART TRANSPLANTATION RECIPIENTS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

2016 ◽  
Vol 67 (13) ◽  
pp. 1356
Author(s):  
Rushi Parikh ◽  
Kiran Khush ◽  
Sean Sana ◽  
Tiffany Daun ◽  
Helen Luikart ◽  
...  
Keyword(s):  
Asymmetric Dimethylarginine ◽  
Enzyme Inhibitors ◽  
Controlled Trial ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Orthotopic Heart Transplantation ◽  
Converting Enzyme ◽  
Double Blind ◽  
Converting Enzyme Inhibitors ◽  
Double Blind Placebo ◽  
The Impact

scholarly journals Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology

2020 ◽  
Vol 7 ◽  
Author(s):  
Sherry-Ann Brown ◽  
Svetlana Zaharova ◽  
Peter Mason ◽  
Jonathan Thompson ◽  
Bicky Thapa ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Management Strategies ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Cancer Therapies ◽  
Converting Enzyme ◽  
Cytokine Release ◽  
Converting Enzyme Inhibitors ◽  
The Impact

Overlapping commonalities between coronavirus disease of 2019 (COVID-19) and cardio-oncology regarding cardiovascular toxicities (CVT), pathophysiology, and pharmacology are special topics emerging during the pandemic. In this perspective, we consider an array of CVT common to both COVID-19 and cardio-oncology, including cardiomyopathy, ischemia, conduction abnormalities, myopericarditis, and right ventricular (RV) failure. We also emphasize the higher risk of severe COVID-19 illness in patients with cardiovascular disease (CVD) or its risk factors or cancer. We explore commonalities in the underlying pathophysiology observed in COVID-19 and cardio-oncology, including inflammation, cytokine release, the renin-angiotensin-aldosterone-system, coagulopathy, microthrombosis, and endothelial dysfunction. In addition, we examine common pharmacologic management strategies that have been elucidated for CVT from COVID-19 and various cancer therapies. The use of corticosteroids, as well as antibodies and inhibitors of various molecules mediating inflammation and cytokine release syndrome, are discussed. The impact of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is also addressed, since these drugs are used in cardio-oncology and have received considerable attention during the COVID-19 pandemic, since the culprit virus enters human cells via the angiotensin converting enzyme 2 (ACE2) receptor. There are therefore several areas of overlap, similarity, and interaction in the toxicity, pathophysiology, and pharmacology profiles in COVID-19 and cardio-oncology syndromes. Learning more about either will likely provide some level of insight into both. We discuss each of these topics in this viewpoint, as well as what we foresee as evolving future directions to consider in cardio-oncology during the pandemic and beyond. Finally, we highlight commonalities in health disparities in COVID-19 and cardio-oncology and encourage continued development and implementation of innovative solutions to improve equity in health and healing.

scholarly journals The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0242314
Author(s):  
Ae-Young Her ◽  
Byoung Geol Choi ◽  
Seung-Woon Rha ◽  
Yong Hoon Kim ◽  
Cheol Ung Choi ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Repeat Revascularization ◽  
History Of ◽  
Receptor Blockers ◽  
The Impact

This study aimed to investigate the impact of angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on 3-year clinical outcomes in acute myocardial infarction (AMI) patients without a history of hypertension who underwent successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES). A total of 13,104 AMI patients who were registered in the Korea AMI registry (KAMIR)-National Institutes of Health (NIH) were included in the study. The primary endpoint was 3-year major adverse cardiac events (MACE), which was defined as the composite of all-cause death, recurrent myocardial infarction (MI), and any repeat revascularization. To adjust baseline potential confounders, an inverse probability weighting (IPTW) analysis was performed. The patients were divided into two groups: the ACEI group, n = 4,053 patients and the ARB group, n = 4,107 patients. During the 3-year clinical follow-up, the cumulative incidences of MACE (hazard ratio [HR], 0.843; 95% confidence interval [CI], 0.740–0.960; p = 0.010), any repeat revascularization (HR, 0.856; 95% CI, 0.736–0.995; p = 0.044), stroke (HR, 0.613; 95% CI, 0.417–0.901; p = 0.013), and re-hospitalization due to heart failure (HF) (HR, 0.399; 95% CI, 0.294–0.541; p <0.001) in the ACEI group were significantly lower than in the ARB group. In Korean patients with AMI without a history of hypertension, the use of ACEI was significantly associated with reduced incidences of MACE, any repeat revascularization, stroke, and re-hospitalization due to HF than those with the use of ARB.

Lisinopril improves arterial function in hyperlipidaemia

1999 ◽  
Vol 96 (5) ◽  
pp. 441-448 ◽  
Author(s):  
Alison F. C. LEE ◽  
John B. C. DICK ◽  
Clare E. BONNAR ◽  
Allan D. STRUTHERS
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Endothelial Function ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Venous Occlusion ◽  
Converting Enzyme ◽  
Double Blind ◽  
Converting Enzyme Inhibitors ◽  
Arterial Function ◽  
Mortality And Morbidity

Endothelial function is defective in hypercholesterolaemia, and animal models have suggested that angiotensin-converting enzyme inhibitors may prevent arterial damage. We studied the effect of 6 months treatment with lisinopril on endothelial function in a group of patients with hypercholesterolaemia. Forty patients were studied. Forearm blood flow responses to acetylcholine and sodium nitroprusside were assessed by venous occlusion plethysmography. Subjects were then randomized in a double-blind fashion to receive either lisinopril, 20 mg/day (n = 20), or placebo (n = 20) for 6 months. Plethysmography was then repeated. Baseline variables between groups were comparable. In the lisinopril group blood pressure fell significantly [systolic: 145±4 to 128±4 mmHg (P< 0.001); diastolic: 84±2 to 74±2 mmHg (P< 0.001)]. An improvement was found in the vasodilatory response (expressed as a ratio of the infused/control arm) to acetylcholine, e.g. 3.33±0.3 (pre) versus 4.45±0.48 (post) at 30 μg/ml (P< 0.03), and also to nitroprusside, e.g. 3.0±0.2 (pre) versus 3.86±0.3 (post) at 3.2 μg/ml (P< 0.01). In the placebo group vasodilatation did not change significantly in response to acetylcholine, and nitroprusside responses were unchanged. The data presented suggest that 6 months of lisinopril therapy have a beneficial effect on arterial function in subjects with hyperlipidaemia. Further work should now investigate whether angiotensin-converting enzyme inhibitors are beneficial in reducing mortality and morbidity in hypercholesterolaemia.

Sign in / Sign up

Export Citation Format

Share Document